SCHEMBL3751208

SCHEMBL3751208

O=C(NCCc1ccccc1)C1c2ccc(O)cc2C(=O)N1CCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 3/20 0.48
PLAAT3 P53816 1/20 0.47
PLAAT5 Q96KN8 1/20 0.47
PLAAT2 Q9NWW9 1/20 0.47
PLAAT4 Q9UL19 1/20 0.47
TP53 P04637 1/20 0.47
LIPG Q9Y5X9 5/20 0.46
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KCNA5 P22460 1/20 0.44
KCNH2 Q12809 1/20 0.44
TRPV1 Q8NER1 1/20 0.43
SCN5A Q14524 1/20 0.42
SCN9A Q15858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3750606 0.85 ALDH1A1 (0.60) KMT2AALDH1A1PLAAT3PLAAT5PLAAT2
SCHEMBL3750571 0.85 ALDH1A1 (0.56) KMT2AALDH1A1PLAAT3PLAAT5PLAAT2
SCHEMBL3751644 0.83 LIPG (0.49) LIPGKCNH2SCN5ASCN9A
SCHEMBL3756505 0.83 KCNA5 (0.56) KMT2ALIPGKCNA5KCNH2
SCHEMBL3753733 0.80 ALDH1A1 (0.62) KMT2AALDH1A1TP53LMNASMN1; SMN2
SCHEMBL3942840 0.80 ALDH1A1 (0.69) KMT2AALDH1A1TP53LMNASMN1; SMN2
SCHEMBL3752652 0.79 KMT2A (0.57) KMT2AALDH1A1TP53LIPGLMNA
SCHEMBL3756760 0.77 KCNA5 (0.70) KMT2AALDH1A1TP53LMNASMN1; SMN2
SCHEMBL3758305 0.76 KMT2A (0.61) KMT2AALDH1A1TP53LIPGLMNA
SCHEMBL3749250 0.76 TP53 (0.53) KMT2AALDH1A1TP53LIPGLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 KMT2A 3483/4885ALDH1A1 315/4885PLAAT3 4233/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 KMT2A 3979/4885ALDH1A1 310/4885PLAAT3 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.